FDA Fast-Tracking New Self-Amplifying “Replicon” mRNA Bird Flu “Vaccine” With Gates Funded Company Arcturus Therapeutics | Supported By Kennedys HHS

SlayNews.com | Frank Bergman

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for a new self-amplifying “replicon” mRNA “vaccine” to supposedly tackle the H5N1 influenza A virus (bird flu).

The fast track was awarded to Arcturus Therapeutics, a Bill Gates-funded company specializing in mRNA-based pharmaceuticals, for its ARCT-2304 mRNA “vaccine.”

One of Arcturus Therapeutics’ senior advisors, former CDC and FDA official Dr. Peter A. Patriarca, also advises the Gates Foundation.

As Slay News has previously reported, the “self-amplifying” or “replicon” mRNA shots contain the equipment needed to make more of itself once it enters cells.

The injections have been dubbed “replicon” vaccines because they are able to replicate inside the human body to produce more mRNA over time.

The new technology has provoked a worldwide backlash from experts and concerned citizens.

Despite concerns about the new injections, federal health officials are rushing the development of the new “replicon” injections.

The designation fast-tracks the development and review of the self-amplifying mRNA (sa-mRNA) vaccine platform.

ARCT-2304 is among the first of its kind aimed at “pandemic flu preparedness.”

The award is particularly notable given the current political environment.

Health and Human Services Secretary Robert F. Kennedy Jr. has promoted a more restrained approach to mass vaccination at the federal level.

Yet, the move to fast-track the replicon “vaccine” was done via the Biomedical Advanced Research and Development Authority (BARDA) funding and HHS support.

The decision to move forward with expedited vaccine development may signal a departure from Kennedy’s earlier posture on “vaccines.”

In a statement about the news, Arcturus President and CEO Joseph Payne said:

“We remain steadfast in our commitment to the U.S. government to develop safe and effective STARR® next-generation mRNA vaccines.

“This designation affirms ARCT-2304’s potential to address a critical public health need.”

The ARCT-2304 (LUNAR-H5N1) candidate utilizes Arcturus’ proprietary LUNAR® delivery system and STARR® platform.

The injection generates many copies of mRNA inside host cells.

It enhances antigen expression at lower doses than traditional mRNA “vaccines.”

Arcturus argues that the lyophilized, refrigerator-stable formulation may also offer critical advantages in cold-chain logistics.

The fast-tracking of a new mRNA “vaccine” under Kennedy’s HHS raises deeper concerns, however.

Many had hoped to see an end to experimental gene therapy products being tested on the general public.

Regulators in Japan were the first to approve the Arcturus ARCT-154 replicon Covid shot for public use.

As Slay News reported, Japanese citizens have been flooding the streets in protest over the injections.

Dr. Robert Malone, the inventor of mRNA technology, said leading experts in Japan describe the new replicon “vaccines” as the “third atomic bomb.”

The approval of the Covid replicon “vaccines” had already triggered major concerns from experts.

In February, unelected eurocrats in the European Union (EU) approved the new Arcturus “self-amplifying” Covid mRNA “vaccines” for use on the general public.

The European Commission, the EU’s primary executive body, approved the so-called “replicon” vaccines for all residents aged 18 and over.

McCullough Foundation epidemiologist Nicolas Hulscher warned that Europe’s approval of ARCT-154 is a “grave mistake.”

“These products behave like a synthetic virus,” Hulscher wrote on Substack.

“The replicon mRNA is designed to encode not only the target antigen but also viral replicase, enabling the mRNA to replicate itself within the target cells.

“This replication machinery allows for an unknown period of toxic antigen production.”

Image: Source [Truth11.com Meme]

Original Article: https://slaynews.com/news/fda-fast-tracks-bill-gates-replicon-mrna-vaccine-bird-flu/